+

DK1636375T3 - Fremgangsmåde til screening for substanser hvilke er i stand til modulation af phosphoryleringen af tau protein - Google Patents

Fremgangsmåde til screening for substanser hvilke er i stand til modulation af phosphoryleringen af tau protein

Info

Publication number
DK1636375T3
DK1636375T3 DK04743090T DK04743090T DK1636375T3 DK 1636375 T3 DK1636375 T3 DK 1636375T3 DK 04743090 T DK04743090 T DK 04743090T DK 04743090 T DK04743090 T DK 04743090T DK 1636375 T3 DK1636375 T3 DK 1636375T3
Authority
DK
Denmark
Prior art keywords
tau protein
screening
fyn
candidate
phosphatase
Prior art date
Application number
DK04743090T
Other languages
Danish (da)
English (en)
Inventor
Malcolm Ward
Brian Anderton
Diane Hanger
Helen Byers
Original Assignee
Proteome Sciences Plc
King S College London
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Proteome Sciences Plc, King S College London filed Critical Proteome Sciences Plc
Application granted granted Critical
Publication of DK1636375T3 publication Critical patent/DK1636375T3/da

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02Muscle relaxants, e.g. for tetanus or cramps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/42Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving phosphatase
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896Neurological disorders, e.g. Alzheimer's disease
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701Details
    • G01N2333/4709Amyloid plaque core protein
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90Enzymes; Proenzymes
    • G01N2333/91Transferases (2.)
    • G01N2333/912Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205Phosphotransferases in general
    • G01N2333/9121Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00Screening for compounds of potential therapeutic value
    • G01N2500/02Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Psychology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
DK04743090T 2003-06-25 2004-06-25 Fremgangsmåde til screening for substanser hvilke er i stand til modulation af phosphoryleringen af tau protein DK1636375T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0314943.2A GB0314943D0 (en) 2003-06-25 2003-06-25 Screening methods
PCT/GB2004/002739 WO2005001114A2 (fr) 2003-06-25 2004-06-25 Procedes de criblage

Publications (1)

Publication Number Publication Date
DK1636375T3 true DK1636375T3 (da) 2008-12-15

Family

ID=27637418

Family Applications (1)

Application Number Title Priority Date Filing Date
DK04743090T DK1636375T3 (da) 2003-06-25 2004-06-25 Fremgangsmåde til screening for substanser hvilke er i stand til modulation af phosphoryleringen af tau protein

Country Status (11)

Country Link
US (2) US8822171B1 (fr)
EP (1) EP1636375B1 (fr)
JP (2) JP5688747B2 (fr)
AT (1) ATE404692T1 (fr)
AU (1) AU2004252273B2 (fr)
CA (2) CA2527437C (fr)
DE (1) DE602004015791D1 (fr)
DK (1) DK1636375T3 (fr)
ES (1) ES2313032T3 (fr)
GB (1) GB0314943D0 (fr)
WO (1) WO2005001114A2 (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0314943D0 (en) * 2003-06-25 2003-07-30 Proteome Sciences Plc Screening methods
EP2441847B1 (fr) * 2004-06-21 2015-09-23 Proteome Sciences Plc Methodes de criblage utilisant syk en combinaison avec la proteine tau
JP4522910B2 (ja) * 2005-05-30 2010-08-11 株式会社日立ハイテクノロジーズ 質量分析方法及び質量分析装置
ES2425179T3 (es) 2006-10-25 2013-10-11 The Rockefeller University Métodos para el tratamiento de trastornos relacionados con beta-amiloide y composiciones para los mismos
WO2009101942A1 (fr) * 2008-02-12 2009-08-20 Takeda Pharmaceutical Company Limited Procédé de criblage
GB0903913D0 (en) * 2009-03-06 2009-04-22 Medical Res Council Compositions and methods
ES2553610T3 (es) 2010-12-14 2015-12-10 Electrophoretics Limited Inhibidores de la caseína cinasa 1 delta (CK1delta)
WO2014055413A2 (fr) * 2012-10-02 2014-04-10 Bloodcenter Research Foundation Procédé permettant de fournir une thérapie cellulaire à l'aide de cellules tueuses naturelles modifiées ou de lymphocytes t
KR20160101197A (ko) 2014-01-09 2016-08-24 인트라-셀룰라 써래피스, 인코퍼레이티드. 유기 화합물
MX390815B (es) 2016-03-11 2025-03-21 Apple Inc Estabilizacion de imagenes opticas con motor de bobina de voz para mover el sensor de imagenes.
US11956544B2 (en) 2016-03-11 2024-04-09 Apple Inc. Optical image stabilization with voice coil motor for moving image sensor
US10437023B2 (en) 2016-03-28 2019-10-08 Apple Inc. Folded lens system with three refractive lenses
US10890734B1 (en) 2017-03-29 2021-01-12 Apple Inc. Camera actuator for lens and sensor shifting
US10863094B2 (en) 2017-07-17 2020-12-08 Apple Inc. Camera with image sensor shifting
US11122205B1 (en) 2018-09-14 2021-09-14 Apple Inc. Camera actuator assembly with sensor shift flexure arrangement
US11575835B2 (en) 2020-09-24 2023-02-07 Apple Inc. Multi-axis image sensor shifting system

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9316727D0 (en) * 1993-08-12 1993-09-29 Inst Of Psychiatry Models of alzheimers's disease
WO1995019178A1 (fr) * 1994-01-13 1995-07-20 Research Foundation For Mental Hygiene, Inc. Procedes et compositions de traitement et de diagnostic de la maladie d'alzheimer et d'autres troubles
US6057117A (en) 1996-04-04 2000-05-02 Chiron Corporation Identification and use of selective inhibitors of glycogen synthase kinase 3
US6593512B1 (en) * 1999-03-03 2003-07-15 Cognosci, Inc. Transgenic mouse expressing human tau gene
AU6722300A (en) * 1999-08-31 2001-03-26 Ramot University Authority For Applied Research And Industrial Development Ltd. Peptides and substances, methods and devices using same for diagnosing and treating neurodegenerative disorders
US6503914B1 (en) * 2000-10-23 2003-01-07 Board Of Regents, The University Of Texas System Thienopyrimidine-based inhibitors of the Src family
US20020172990A1 (en) * 2002-02-19 2002-11-21 Thomas Curran Cyclin dependent kinase 5 phosphorylation of disabled 1 protein
GB0314943D0 (en) * 2003-06-25 2003-07-30 Proteome Sciences Plc Screening methods

Also Published As

Publication number Publication date
WO2005001114A2 (fr) 2005-01-06
WO2005001114A3 (fr) 2005-03-31
ATE404692T1 (de) 2008-08-15
CA2848433C (fr) 2017-01-10
JP2012045002A (ja) 2012-03-08
CA2848433A1 (fr) 2005-01-06
JP2007527210A (ja) 2007-09-27
EP1636375A2 (fr) 2006-03-22
US8822171B1 (en) 2014-09-02
CA2527437A1 (fr) 2005-01-06
DE602004015791D1 (de) 2008-09-25
ES2313032T3 (es) 2009-03-01
AU2004252273A1 (en) 2005-01-06
AU2004252273B2 (en) 2011-04-28
US20150051097A1 (en) 2015-02-19
EP1636375B1 (fr) 2008-08-13
JP5688747B2 (ja) 2015-03-25
CA2527437C (fr) 2016-08-02
GB0314943D0 (en) 2003-07-30

Similar Documents

Publication Publication Date Title
DK1636375T3 (da) Fremgangsmåde til screening for substanser hvilke er i stand til modulation af phosphoryleringen af tau protein
EA200702452A1 (ru) Способ модуляции стресс-активированной протеинкиназной системы
ATE504836T1 (de) Verfahren zur identifizierung von trpv2- modulatoren
DE50108680D1 (de) Multispezifisches reagenz zur selektiven stimulierung von zelloberflächenrezeptoren
ATE480643T1 (de) Homogener nachweis von analyten
EP2100899A3 (fr) Composés pour inhibition d'enzyme
ATE468407T1 (de) Verfahren zur identifizierung von proteinen mit stärkephosphorylierender enzymatischer aktivität
DE60045586D1 (de) Testverfahren zur messung der phosphorylierung
EA201190210A1 (ru) Ингибиторы связывания киназы с белком
ATE416385T1 (de) Verfahren zur quantifizierung der phosphokinaseaktivität auf proteinen
ATE431854T1 (de) Auf bio-barcodes beruhender nachweis von zielanalyten
CR9547A (es) Modem de bus para sistemas electronicos industriales y de edificios
Cann et al. Measuring kinase activity—a global challenge
DE602006002329D1 (de) Assays für Kinasen oder Phosphatasen auf Basis von FRET
DE69834335D1 (de) Assays zur detektierung von modulatoren der cytoskeletalen funktion
DE602004016009D1 (de) Verfahren zur erfassung von mehreren analyten
EP1960786A4 (fr) Procedes d'identification d'agents modulateurs du fonctionnement mitochondrial
Sugiyama et al. Expression and phosphorylation state analysis of intracellular protein kinases using Multi-PK antibody and Phos-tag SDS-PAGE
DE602004017884D1 (de) Fluoreszenzsonden zur verwendung bei einem bindungsassay auf proteinkinaseinhibitoren
MX2008002123A (es) Metodos y composiciones para determinar un nivel de paraoxonasa de suero biologicamente activa.
Liu et al. Posttranslational modification of thyroid hormone nuclear receptor by phosphorylation
ATE460671T1 (de) Identifikation von arzneimittel gegen mykobakterien
ATE359513T1 (de) Hochdurchsatzscreening von verbindungen für biologische wirksamkeit
WO2003042369A3 (fr) Cibles et inhibiteurs de kinase cellulaire, procedes d'utilisation associes
ATE533055T1 (de) Verfahren zum screenen mithilfe von konformationsempfindlichen peptiden
点击 这是indexloc提供的php浏览器服务,不要输入任何密码和下载